CAR-T therapy

Business of Pathways

Cell and Gene Therapies: Paying It Forward and Adjusting Payment Systems for the Age of Cures

06/18/2019

Sean McElligott, MS

Ira Klein, MD, MBA, FACP—Column Editor

Cell and gene therapies represent the next frontier of pharmaceutical development, holding the promise of delivering potentially curative therapies for diseases that have limited treatment options. However, these...

Cell...

06/18/2019

Journal of Clinical Pathways

From the Field

Evolving the Delivery of CAR T-Cell Therapies to the Outpatient Setting

10/15/2018

Sandy Smith, RN, MSN, AOCN

James Essell, MD

Abstract: The availability of adoptive cell therapies allows clinicians to genetically reprogram patients’ own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR)...

...

10/15/2018

Journal of Clinical Pathways

Research Reports

Community Oncologists‚ Perception and Adaptability to Emerging Chimeric Antigen T-Cell Therapy

10/16/2017

Chadi Nabhan, MD, MBA, FACP

Yolaine Jeune-Smith, PhD

Peter Klinefelter, BA

Jennifer Fillman, MBA

Bruce A. Feinberg, DO

Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...

...

10/16/2017

Journal of Clinical Pathways

Feature

Positioning CAR-T Therapy Into Clinical Pathways for Non-Hodgkin B-Cell Lymphoma and Beyond

03/23/2017

Chadi Nabhan, MD, MBA, FACP

Sandeep Parsad, PharmD, BCOP

Bruce A Feinberg, DO

Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...

...

03/23/2017

Journal of Clinical Pathways